兆科眼科(06622.HK)NVK002中国第III期临床试验取得积极顶线结果

阿斯达克财经10-23

兆科眼科-B(06622.HK) 公布，公司核心产品之一NVK002为期两年的第III期临床试验的顶线结果显示，NVK002滴眼液组对比安慰剂组在主要疗效指标上有统计学意义的显著性差异，NVK002滴眼液组优于安慰剂组，而且具有剂量依赖。两种剂量的NVK002安全性良好，患者使用依从性好。公司指，临床试验主要目标为评估NVK002对治疗内地儿童及青少年近视加深的疗效及安全性。该项试验涉及18间中心...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2477467309?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210624120657847_s.jpg","is_english":false,"pubTime":"2024-10-23 17:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477467309","market":"sh","top_or_hot":-1,"title":"兆科眼科(06622.HK)NVK002中国第III期临床试验取得积极顶线结果","media":"阿斯达克财经","content":"<div>\n<p>兆科眼科-B(06622.HK) 公布，公司核心产品之一NVK002为期两年的第III期临床试验的顶线结果显示，NVK002滴眼液组对比安慰剂组在主要疗效指标上有统计学意义的显著性差异，NVK002滴眼液组优于安慰剂组，而且具有剂量依赖。两种剂量的NVK002安全性良好，患者使用依从性好。公司指，临床试验主要目标为评估NVK002对治疗内地儿童及青少年近视加深的疗效及安全性。该项试验涉及18间中心...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1390505/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>兆科眼科(06622.HK)NVK002中国第III期临床试验取得积极顶线结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n兆科眼科(06622.HK)NVK002中国第III期临床试验取得积极顶线结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-23 17:50 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1390505/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>兆科眼科-B(06622.HK) 公布，公司核心产品之一NVK002为期两年的第III期临床试验的顶线结果显示，NVK002滴眼液组对比安慰剂组在主要疗效指标上有统计学意义的显著性差异，NVK002滴眼液组优于安慰剂组，而且具有剂量依赖。两种剂量的NVK002安全性良好，患者使用依从性好。公司指，临床试验主要目标为评估NVK002对治疗内地儿童及青少年近视加深的疗效及安全性。该项试验涉及18间中心...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1390505/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06622","symbol_name":"兆科眼科-B","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1390505/latest-news/AAFN","article_id":"2477467309","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210624120657847_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477467309","pubTimestamp":1729677000,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"兆科眼科-B(06622.HK) 公布，公司核心产品之一NVK002为期两年的第III期临床试验的顶线结果显示，NVK002滴眼液组对比安慰剂组在主要疗效指标上有统计学意义的显著性差异，NVK002滴眼液组优于安慰剂组，而且具有剂量依赖。两种剂量的NVK002安全性良好，患者使用依从性好。公司指，临床试验主要目标为评估NVK002对治疗内地儿童及青少年近视加深的疗效及安全性。该项试验涉及18间中心，入组777名患者。(vc/a)(港股报价延迟最少十五分钟。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06622":"兆科眼科-B","BK1141":"生命科学工具和服务","BK1191":"制药","BK1574":"生物医药B类股","BK1576":"医药外包概念","BK1587":"次新股","BK1583":"高瓴概念","03347":"泰格医药"},"translate_title":"Zhaoke Ophthalmology (06622. HK) NVK002 China Phase III clinical trial achieved positive top-line results","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03347":1,"06622":1},"content_text":"兆科眼科-B(06622.HK) 公布，公司核心产品之一NVK002为期两年的第III期临床试验的顶线结果显示，NVK002滴眼液组对比安慰剂组在主要疗效指标上有统计学意义的显著性差异，NVK002滴眼液组优于安慰剂组，而且具有剂量依赖。两种剂量的NVK002安全性良好，患者使用依从性好。公司指，临床试验主要目标为评估NVK002对治疗内地儿童及青少年近视加深的疗效及安全性。该项试验涉及18间中心，入组777名患者。(vc/a)(港股报价延迟最少十五分钟。)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477467309"}